EBC-129 Receives FDA Fast-Track Designation for PDAC

Novel ADC Receives FDA Fast Track Designation for Pancreatic Cancer

The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.

PDAC antibody-drug conjugate EBC-129 wins FDA fast track designation

U.S. regulators have granted fast track status to the Experimental Drug Development Centre’s (EDDC’s) candidate therapy for pancreatic ductal adenocarcinoma (PDAC), an aggressive form of pancreatic cancer. The decision by the Food and Drug Administration (FDA) will expedite the development of EBC-129, an antibody-drug conjugate (ADC) that’s being tested for PDAC and other types of solid tumors. “The FDA’s fast track designation for EBC-129 under…

FDA Fast-Tracks Novel ADC in Pancreatic Cancer

EBC-129 has been granted FDA fast track designation for the treatment of pancreatic ductal adenocarcinoma, paving the way for development of this antibody-drug conjugate.

EBC-129 Receives FDA Fast-Track Designation for PDAC

Clinical data from a phase 1 trial evaluating EBC-129 in solid tumors will be presented at the 2025 American Society of Clinical Society Annual Meeting.